WuXi Biologics
Offering End-to-End Solutions
WuXi Vaccines, a subsidiary of WuXi Biologics, focuses on human vaccine discovery, development and manufacture. An exciting new addition to the WuXi Biologics family, WuXi Vaccines will bring to the global vaccine industry the world-class integrated platforms and CDMO business model on which WuXi Biologics reputation is based.
In development is an integrated vaccine manufacturing facility with 240 million US Dollar investment, including drug substance manufacturing (DS), drug product manufacturing (DP), Manufacture Science and Technology Labs (MS&T) as well as Quality Control labs (QC), dedicated to manufacturing our partner’s vaccine products for the global market. It is expected to be operational in 2022. It will bring 200 additional new jobs to Dundalk town over five years.
Invest $240 million
Creation of 200 highly-skilled jobs
这个基地将坐落于位于M1高速公路17号出口旁,爱尔兰发展协会敦多克科技园内。早在2008年当地就在规划这个生物技术园区了。
有关M1发展带的更多信息,请访问网站://www.m1corridor.ie/
您将离开药明生物公司所属网站,跳转后将不再适用我们的《隐私声明》,请注意保护好您的个人隐私。您是否希望继续?